Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy

Summary

This prospective case-control study investigated the potential of circulating cell-free DNA (cfDNA) as a non-invasive biomarker for ovarian cancer. Researchers quantified cfDNA levels in 50 ovarian cancer patients, 50 patients with benign ovarian lesions, and 50 controls. Results revealed significantly higher cfDNA levels in the malignant group. cfDNA demonstrated strong discriminatory capability for predicting ovarian cancer, its late stage, and mortality, with high AUC values. The study concludes that cfDNA could serve as a diagnostic and prognostic biomarker for ovarian cancer, supporting its use in risk stratification and treatment planning.

Critical appraisal

This prospective case-control study, effectively a phase II biomarker evaluation, positions cfDNA as a promising diagnostic and prognostic biomarker for ovarian cancer. The high AUC values (0.934 for diagnosis, 0.993 for late-stage prediction, 0.814 for mortality) indicate strong discriminatory power. These findings suggest cfDNA could significantly enhance risk stratification and treatment planning, potentially guiding the selection of aggressive therapies for patients with high cfDNA expression. This evidence warrants further validation in larger, prospective phase III trials to integrate cfDNA into screening or monitoring protocols, with a potential clinical impact within 3-5 years.

The study utilized real-time PCR for cfDNA quantification, demonstrating its analytical validity in distinguishing ovarian cancer patients from controls and those with benign lesions based on distinct mean concentrations. As a circulating biomarker obtained from liquid biopsy, cfDNA offers a non-invasive approach. Its strong correlation with tumor grade and independent prognostic value for progression-free and overall survival highlight its translational potential for developing clinical diagnostic and monitoring assays, paving the way for personalized treatment strategies.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology